Clinical trials: Coagulation Protein Disorders
Severe Hemophilia B
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B
The primary objectives of the study were: to evaluate the safety and tolerability of rFIXFc; to evaluate the efficacy of rFIXFc in all treatment arms; to evaluate the effectiveness of prophylaxis over on-demand (episodic) therapy…
- Trial name
- NCT01027364
- Testing
- Factor IX (rFIXFc), rFIX
- Where
- 51 sites in United States, Australia and 15 more
- Volunteers
- 123 people
- Sponsor
- Bioverativ Therapeutics Inc.
Hemophilia B
Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use
This is an open-label multi-center Registry in patients with hemophilia B receiving BeneFIX. All patients who begin treatment with BeneFIX in European Union countries, will be eligible for participation.
- Trial name
- NCT00167973
- Where
- 90 sites in Austria, Belgium and 8 more
- Volunteers
- 218 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer